Remdesivir for the treatment of Covid-19—preliminary report
BACKGROUND: Although several therapeutic agents have been evaluated for the treatment
of coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be
efficacious. METHODS: We conducted a double-blind, randomized, placebo-controlled trial
of intravenous remdesivir in adults who were hospitalized with Covid-19 and had evidence
of lower respiratory tract infection. Patients were randomly assigned to receive either
remdesivir (200 mg loading dose on day 1, followed by 100 mg daily for up to 9 additional …
of coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be
efficacious. METHODS: We conducted a double-blind, randomized, placebo-controlled trial
of intravenous remdesivir in adults who were hospitalized with Covid-19 and had evidence
of lower respiratory tract infection. Patients were randomly assigned to receive either
remdesivir (200 mg loading dose on day 1, followed by 100 mg daily for up to 9 additional …
[HTML][HTML] Remdesivir for the treatment of Covid-19
Background Although several therapeutic agents have been evaluated for the treatment of
coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be
efficacious. Methods We conducted a double-blind, randomized, placebo-controlled trial of
intravenous remdesivir in adults who were hospitalized with Covid-19 and had evidence of
lower respiratory tract infection. Patients were randomly assigned to receive either
remdesivir (200 mg loading dose on day 1, followed by 100 mg daily for up to 9 additional …
coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be
efficacious. Methods We conducted a double-blind, randomized, placebo-controlled trial of
intravenous remdesivir in adults who were hospitalized with Covid-19 and had evidence of
lower respiratory tract infection. Patients were randomly assigned to receive either
remdesivir (200 mg loading dose on day 1, followed by 100 mg daily for up to 9 additional …